Skip to main content
Premium Trial:

Request an Annual Quote

Cell Signaling Technology to Conduct Biomarker Study for Aventis

NEW YORK, Sept. 21 (GenomeWeb News) - Cell Signaling Technology said today that it has signed an agreement with Aventis to conduct a pilot study in which CST will identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets for Aventis.

 

Under the terms of the agreement, CST, based in Beverly, Mass., will use its PhosphoScan technology to identify the biomarkers, which may enable target validation and profiling assays to monitor kinase-targeted therapeutic pharmacodynamics and efficacy, CST said.

 

PhosphoScan, according to the company, is patent-pending phospho-proteomics technology that combines immunoaffinity purification and mass spectroscopy to determine cellular PTK phosphorylation profiles.

 

Financial terms of the deal were not disclosed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.